Clinical trials: Nasal Allergy
- Condition Nasal Allergy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Allergic Rhinitis
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis
- Trial name
- NCT01794741
- Testing
- Dymista Nasal Spray, Fluticasone propionate nasal spray
- Where
- 41 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Meda Pharmaceuticals
Asthma
Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers
This is a randomized, double-blind, placebo-controlled Phase 1 study of HA115 capsules administered orally to healthy adult volunteers.
- Trial name
- NCT03567694
- Testing
- HA115
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Healthy, Asthma
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent…
- Trial name
- NCT02243189
- Testing
- JNJ-43260295, Nasal Allergen Challenge
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Allergic Rhinitis
Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
The purpose of this study is to compare the systemic levels of beclomethasone 17 monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP HFA with the systemic levels of 17 BMP after…
- Trial name
- NCT01537692
- Testing
- BDP HFA Nasal Aerosol, BDP HFA Inhalation Aerosol (QVAR)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Allergic Rhinitis
Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity
This study will evaluate whether multiple nasal antigen challenges with dust mite allergen produces increases in nasal symptoms and local allergic inflammatory cells in the nose and the blood.
- Trial name
- NCT00513487
- Testing
- Dust mite extract, Fluticasone, Methacholine
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novartis
Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis
Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.
This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple…
- Trial name
- NCT06038279
- Testing
- INI-2004
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Inimmune Corporation
Allergy Pollen
Microassay and Allergy Skin Prick Test Correlation Study
The purpose of this study is to evaluate the potential correlation of the results of allergen-specific skin prick tests (SPT) to that of allergen-specific microarray determination (microassay test).
- Trial name
- NCT03514303
- Testing
- Spiriplex Allergenex Microassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Respiratory Disorders, Asthma and Rhinitis
Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions
This study is conducted to determine whether the test product (GW483100 10 mg containing montelukast sodium equivalent to 10 mg of montelukast) is bioequivalent to the reference montelukast sodium 10 mg tablets (innovator…
- Trial name
- NCT02658422
- Testing
- Test Montelukast, Reference Montelukast
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
The purpose of this study is to evaluate the effects of allergic rhinitis (group of symptoms affecting the nose) and co-administration of mometasone or oxymetazoline on the pharmacokinetics (explores what the body does to the…
- Trial name
- NCT02154334
- Testing
- Esketamine, Mometasone, Oxymetazoline
- Where
- Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Asthma, Rhinitis, Allergic, Perennial
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
The primary objective of the current study is to investigate the safety and tolerability of BI 671800 HEA in healthy Chinese male volunteers following single oral administration, and healthy Japanese male volunteers following…
- Trial name
- NCT01216384
- Testing
- BI 671800
- Where
- South Korea
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Allergic Rhinitis, Rhinoconjunctivitis
Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects
To assess the reproducibility of the allergic response in the cat allergic subjects, measured as the change from baseline of the Total Nasal Symptom Score (TNSS) on the two challenge days.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Exposure
- Trial name
- NEC (NCT03414801)
- Testing
- Allergen Exposure
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Red Maple Trials Inc.
Allergic Rhinitis
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
- Trial name
- NCT00929968
- Testing
- VAK694, Fluticasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Perennial
Long Term Safety Of GW685698X Via Nasal Biopsy
Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis .
- Trial name
- NCT00224523
- Testing
- GW685698X, mometasone furoate
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anaphylaxis
Bioavailability of Nasal Epinephrine
A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder with Epinephrine 0.3 mg Intramuscular Injection in Adult Subjects with Seasonal Allergic Rhinitis with and…
- Trial name
- NCT04696822
- Testing
- Epinephrine Nasal Product, 1.6 mg, Epinephrine nasal product, 1.6 mg + allergen, Epinephrine Injection 0.3 mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Allergic Rhinitis, Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
This study is an 8 day, randomised, double blind, 2-way crossover trial of repeat doses of intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612118
- Testing
- GSK256066, azelastine hydrochloride
- Where
- Austria
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nasal Allergies, Allergies
Safety and Efficacy of AL-53817 Nasal Spray Solution
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
- Trial name
- NCT01454505
- Testing
- AL-53817 nasal spray solution, Vehicle nasal spray
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Rhinitis, Allergic, Perennial
Single Dosing Clinical Trial of HL151
The purpose of this study is to assess the pharmacokinetic characteristics of bepotastine after single oral administration of TALION tab, a IR formulation of bepotastine as reference drug and HL151, a SR formulation of…
- Trial name
- NCT02682745
- Testing
- HL151, TALION tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Birch Pollen Allergy
Study of DM-101PX in Adults With Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults.
- Trial name
- BASIT (NCT07254871)
- Testing
- DM-101PX
- Where
- Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Desentum Oy
Allergic Asthma
A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers
This is a phase I an open-label randomized comparative study in parallel groups of pharmacokinetics, pharmacodynamics, immunogenicity, and safety of Genolair in two dosage forms (solution for subcutaneous administration and…
- Trial name
- NCT06494345
- Testing
- Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg
- Where
- Russia
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM